| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic therapeutics, has been granted a U.S. patent for its drug candidate EB-002. The license, No. 11,945,778, issued by the United States Patent and Trademark Office, includes broad claims for treating brain neurological disorders.
This achievement enhances Enveric’s intellectual property protection for EB-002, covering treatment methods for a variety of neurological conditions, including sleep disorders, depression, substance-related disorders and headaches. EB-002, a next-generation psilocin prodrug, is currently under development for neuropsychiatric disorders, initially focusing on anxiety.
Joseph Tucker, Ph.D., CEO of Enveric, emphasized the importance of this patent: "EB-002, the lead compound from Enveric's EVM201 screening program, now enjoys U.S. patent coverage under three issued patents. These include compositions and pharmaceutical formulations of EB-002 (US 11,707,447), methods of making the molecules (US 11,845,726), and now methods of treating a broad range of brain neurological disorders (US 11,945,778). PCT patent applications are also pending."
Dr. Tucker added, "Deploying comprehensive patent portfolios to protect lead drug development candidates helps to de-risk and accelerate clinical development, furthering the Company's efforts to rapidly bring this new drug to patients."
Cover image made with AI
Posted In: ENVB
